Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.
- DOI
- 10.1016/j.jcte.2023.100320
- Published
- 2023 Sep
- Container
- Journal of clinical & translational endocrinology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jcte.2023.100320,
title = {Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.},
author = {Lurquin F and Gohy S and Hermans MP and Preumont V},
year = {2023},
journal = {Journal of clinical \& translational endocrinology},
doi = {10.1016/j.jcte.2023.100320},
url = {https://doi.org/10.1016/j.jcte.2023.100320}
}RIS
TY - JOUR TI - Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes. AU - Lurquin F AU - Gohy S AU - Hermans MP AU - Preumont V PY - 2023 JO - Journal of clinical & translational endocrinology DO - 10.1016/j.jcte.2023.100320 UR - https://doi.org/10.1016/j.jcte.2023.100320 ER -
APA
F, L., S, G., MP, H., & V, P. (2023). Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.. Journal of clinical & translational endocrinology. https://doi.org/10.1016/j.jcte.2023.100320
Source records
- pubmed · retrieved 2026-09-26T21:45:47.789Z